Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Receivables - Accured (2023 - 2025)

Century Therapeutics (IPSC) has disclosed Receivables - Accured for 2 consecutive years, with $1.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Receivables - Accured fell 20.13% to $1.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.3 million, a 20.13% decrease, with the full-year FY2024 number at $1.3 million, down 20.13% from a year prior.
  • Receivables - Accured was $1.3 million for Q4 2024 at Century Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $1.6 million in Q4 2023 to a low of $855000.0 in Q1 2023.